Research ArticleOriginal Research

Patient Perspective on Watchful Waiting/Active Surveillance for Localized Prostate Cancer

Jinping Xu, Anne Victoria Neale, Rhonda K. Dailey, Susan Eggly and Kendra L. Schwartz
The Journal of the American Board of Family Medicine November 2012, 25 (6) 763-770; DOI: https://doi.org/10.3122/jabfm.2012.06.120128

References

  1. 1.↵
    1. Welch HG,
    2. Albertsen PC
    . Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 2009;101:1325–9.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Welch HG,
    2. Black WC
    . Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605–13.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Roemeling S,
    2. Roobol MJ,
    3. de Vries SH,
    4. et al
    . Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics. PSA doubling times, and outcome. Eur Urol 2007;51:1244–51.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Draisma G,
    2. Boer R,
    3. Otto SJ,
    4. et al
    . Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Draisma G,
    2. Etzioni R,
    3. Tsodikov A,
    4. et al
    . Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374–83.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Heijnsdijk EA,
    2. der Kinderen A,
    3. Wever EM,
    4. et al
    . Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 2009;101:1833–8.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Mohler J,
    2. Bahnson RR,
    3. Boston B,
    4. et al
    . NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8:162–200.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Johansson JE,
    2. Andren O,
    3. Andersson SO,
    4. et al
    . Natural history of early, localized prostate cancer. JAMA 2004;291:2713–9.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Klotz L,
    2. Zhang L,
    3. Lam A,
    4. et al
    . Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126–31.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Stattin P,
    2. Holmberg E,
    3. Johansson JE,
    4. et al
    . Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010;102:950–8.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Lu-Yao GL,
    2. Albertsen PC,
    3. Moore DF,
    4. et al
    . Outcomes of localized prostate cancer following conservative management. JAMA 2009;302:1202–9.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Harlan SR,
    2. Cooperberg MR,
    3. Elkin EP,
    4. et al
    . Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003;170:1804–7.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Miller DC,
    2. Gruber SB,
    3. Hollenbeck BK,
    4. et al
    . Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134–41.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Cooperberg MR,
    2. Broering JM,
    3. Carroll PR
    . Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117–23.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Dall'Era MA,
    2. Cooperberg MR,
    3. Chan JM,
    4. et al
    . Active surveillance for early stage prostate cancer: review of the current literature. Cancer 2008;112:1650–9.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Klotz L
    . Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165–9.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Allaf ME,
    2. Carter HB
    . Update on watchful waiting for prostate cancer. Curr Opin Urol 2004;14:171–5.
    OpenUrlPubMed
  18. 18.↵
    1. Bailey DE Jr.,
    2. Wallace M
    . Critical review: is watchful waiting a viable management option for older men with prostate cancer? Am J Mens Health 2007;1:18–28.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Steinberg GD,
    2. Bales GT,
    3. Brendler CB
    . An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431–6.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Parker C
    . Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004;5:101–6.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Thompson I,
    2. Thrasher JB,
    3. Aus G,
    4. et al
    . Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106–31.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Chapple A,
    2. Ziebland S,
    3. Herxheimer A,
    4. et al
    . Is “watchful waiting” a real choice for men with prostate cancer? A qualitative study. BJU Int 2002;90:257–64.
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Holmboe ES,
    2. Concato J
    . Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med 2000;15:694–701.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Schwartz K,
    2. Powell IJ,
    3. Underwood W 3rd.,
    4. et al
    . Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology 2009;74:1296–302.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Shavers VL,
    2. Brown ML,
    3. Potosky AL,
    4. et al
    . Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 2004;19:146–55.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Harlan LC,
    2. Potosky A,
    3. Gilliland FD,
    4. et al
    . Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001;93:1864–71.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Krupski TL,
    2. Kwan L,
    3. Afifi AA,
    4. Litwin MS
    . Geographic and socioeconomic variation in the treatment of prostate cancer. J Clin Oncol 2005;23:7881–8.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Steenland K,
    2. Goodman M,
    3. Liff J,
    4. et al
    . The effect of race and rural residence on prostate cancer treatment choice among men in Georgia. Urology 2011;77:581–7.
    OpenUrlPubMed
  29. 29.↵
    1. Zeliadt SB,
    2. Ramsey SD,
    3. Penson DF,
    4. et al
    . Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006;106:1865–74.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Steenland K,
    2. Goodman M,
    3. Liff J,
    4. et al
    . Quality of life among men with prostate cancer in rural Georgia. Urology 2011;77:927–33.
    OpenUrlPubMed
  31. 31.↵
    1. Katz SJ,
    2. Lantz PM,
    3. Janz NK,
    4. et al
    . Patient involvement in surgery treatment decisions for breast cancer. J Clin Oncol 2005;23:5526–33.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Hu JC,
    2. Kwan L,
    3. Krupski TL,
    4. et al
    . Determinants of treatment regret in low-income, uninsured men with prostate cancer. Urology 2008;72:1274–9.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Xu J,
    2. Dailey RK,
    3. Eggly S,
    4. et al
    . Men's perspectives on selecting their prostate cancer treatment. JNMA 2011;103:468–78.
    OpenUrl
  34. 34.↵
    1. Rosenstock IM,
    2. Strecher VJ,
    3. Becker MH
    . Social learning theory and the Health Belief Model. Health Educ Q 1988;15:175–83.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Krantz DS,
    2. Baum A
    1. Miller SM,
    2. Diefenbach MA
    . The Cognitive-Social Health Information Processing (C-SHIP) model: a theoretical framework for research in behavioral oncology. In Krantz DS, Baum A, (eds). Technology and Methods in Behavioral Medicine. Mahwah, NJ: Lawrence Erlbaum; 1998:219–44.
  36. 36.↵
    1. Crabtree BF,
    2. Miller WL
    1. Miller WL,
    2. Crabtree BF
    . Clinical research: a multimethod typology and qualitative roadmap. In Crabtree BF, Miller WL, (eds). Doing qualitative research. 2nd edition. Thousand Oaks: Sage Publications; 1999;3–30.
  37. 37.↵
    1. Strauss A CJ
    . Basics of qualitative research: grounded theory procedures and techniques. Newbury Park: Sage Publications; 1990.
  38. 38.↵
    1. Lin K,
    2. Croswell JM,
    3. Koenig H,
    4. Lam C,
    5. Maltz A
    . Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Evidence synthesis number 90. AHRQ Publication No. 12–05160-EF-1. October 2011. Available at http://www.uspreventiveservicestaskforce.org/uspstf12/prostate/ prcascres.pdf. Accessed September 11, 2012.
  39. 39.↵
    1. Harris G
    . U.S. panel says no to prostate screening for healthy men [press release online]. New York Times. October 6, 2011. Available at http://www.nytimes.com/2011/10/07/health/07prostate.html. Accessed October 14 2011.
  40. 40.
    1. Carroll PR
    . Early stage prostate cancer–do we have a problem with over-detection, overtreatment or both? J Urol 2005;173:1061–2.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    National Institutes of Health State-of-the-Science Conference Statement. The role of active surveillance in the management of men with localized prostate cancer. Available at http://consensus.nih.gov/2011/docs/prostate/ASPC%20Final%20Draft%20Statement.pdf. Accessed January 6, 2012.
  42. 42.↵
    1. O'Rourke ME
    . Narrowing the options: the process of deciding on prostate cancer treatment. Cancer Invest 1999;17:349–59.
    OpenUrlPubMedWeb of Science
  43. 43.↵
    1. Davison BJ,
    2. Oliffe JL,
    3. Pickles T,
    4. Mroz L
    . Factors influencing men undertaking active surveillance for the management of low-risk prostate cancer. Oncol Nurs Forum 2009;36:89–96.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    1. Gorin MA,
    2. Soloway CT,
    3. Eldefrawy A,
    4. Soloway MS
    . Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology 2011;77:588–91.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Demark-Wahnefried W,
    2. Schildkraut JM,
    3. Iselin CE,
    4. et al
    . Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer 1998;83:320–30.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    1. Moul JW,
    2. Douglas TH,
    3. McCarthy WF,
    4. McLeod DG
    . Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 1996;155:1667–73.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Amling CL,
    2. Riffenburgh RH,
    3. Sun L,
    4. et al
    . Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439–45.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Freedland SJ,
    2. Jalkut M,
    3. Dorey F,
    4. et al
    . Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology 2000;56:87–91.
    OpenUrlPubMedWeb of Science
  49. 49.↵
    1. Resnick MJ,
    2. Canter DJ,
    3. Guzzo TJ,
    4. et al
    . Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy? Urology 2009;73:620–3.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. McVey GP,
    2. McPhail S,
    3. Fowler S,
    4. et al
    . Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 2010;106:1161–4.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Payer L
    . Medicine and culture: varieties of treatment in the United States, England, West Germany, and France. New York: Henry Holt and Company; 1996.
  52. 52.↵
    National Cancer Institute. National Cancer Act of 1971. Available at http://dtp.nci.nih.gov/timeline/noflash/milestones/M4    Nixon.htm. Accessed November 12, 2011.
  53. 53.↵
    American Cancer Society. Cancer facts & figures 2011. Available at http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011. Accessed December 11, 2011.
  54. 54.↵
    1. Denberg TD,
    2. Melhado TV,
    3. Steiner JF
    . Patient treatment preferences in localized prostate carcinoma: The influence of emotion, misconception, and anecdote. Cancer 2006;107:620–30.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Berry DL,
    2. Ellis WJ,
    3. Woods NF,
    4. et al
    . Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol Oncol 2003;21:93–100.
    OpenUrlPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords